Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelcitoclax and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05691504Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2023
- Primary completion
- Feb 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelcitoclax in ovarian cancer, endometrial cancer (EC), fallopian tube cancer (PFTC) and 1 more, sponsored by National Cancer Institute. Primary endpoints: Maximum tolerable dose, Recommended phase 2 dose and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
pelcitoclax
03
Conditions
ovarian cancerendometrial cancer (EC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05691504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691504.